Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. RESEARCH DESIGN AND METHODS: This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of ≥5% weight loss. Secondary end points included achievement of HbA1c <7% (53 mmol/mol), achievement of weight loss ≥10%, and change in HbA1c, waist circumference, fasting blood glucose, and lipids. RESULTS: In the modified intent-to-treat population (54% female, 80% Caucasian, and mean age 54 years, weight 106 kg, BMI 37 kg/m2, and HbA1c 8.0% [64 mmol/mol]), NB resulted in significantly greater weight reduction (−5.0 vs. −1.8%; P < 0.001) and proportion of patients achieving ≥5% weight loss (44.5 vs. 18.9%, P < 0.001) compared with placebo. NB also resulted in significantly greater HbA1c reduction (−0.6 vs. −0.1% [6.6 vs. 1.1 mmol/mol]; P < 0.001), percent of patients achieving HbA1c <7% (53 mmol/mol) (44.1 vs. 26.3%; P < 0.001), and improvement in triglycerides and HDL cholesterol compared with placebo. NB was associated with higher incidence of nausea (42.3 vs. 7.1%), constipation (17.7 vs. 7.1%), and vomiting (18.3 vs. 3.6%). No difference was observed between groups in the incidence of depression, suicidal ideation, or hypoglycemia. CONCLUSIONS: NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Even so, in subanalyses, persons losing more than 10% of weight at 1 year experienced a 21% reduction in the composite CVD outcome.734”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [734]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar attenuation in weight loss in patients with vs without type 2 diabetes has been observed with other AOM, including orlistat,(44) naltrexone-bupropion,(45) and liraglutide 3.0 mg,(46) as well as with some behavioral interventions.(47, 48)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“In COR-Diabetes, naltrexone/bupropion yielded − 5% weight loss and − 0.6% HbA1c reductions [35].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [35]
In the citing paper
“Naltrexone plus bupropion extended-release reduces weight on average by ≈7% (≈5% placebo-subtracted) [51][52][53][54] and also more than either agent administered alone.55”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [52]
In the citing paper
“Other AOMs have yielded comparably smaller weight losses in patients with versus without type 2 diabetes [58].”
From The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023) · cites this paper as [58]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Christiane, Druml, Wolzt, & Pleiner (2001) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 3,419
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 2×
“Furthermore, naltrexone and bupropion therapy are believed to influence the mesolimbic dopaminergic reward system,which canmodulate reward behaviors such as food intake (14,15).”
Background
Research works printed but not linked: 1
- Sinnayah, 2007, Bupropion and naltrexone interact synergistically to decrease food intake in mice, Obesity (Silver Spring), 15, A179
Cited by
Items 401–500 of 500
Research Progress of Slimming Products and Their Pharmacological Mechanisms
梁, 淑. (2022) · Hans Journal of Food and Nutrition Science · doi:10.12677/hjfns.2022.111009 · Cited by 1
Obesity as a Neurobiologic Disorder: A Heavyweight Contender
Chávez-Castillo, M., Durán, P., Garrido, B., Díaz, A., Escalona, D., & Cano, C. (2022) · Current Psychiatry Research and Reviews · doi:10.2174/2666082218666220527120848 · Cited by 2
Mazaheri, T., Ansari, S., Nallagonda, M., Kollmann, L., Nickel, F., Seyfried, F., & Miras, A. D. (2023) · Die Chirurgie · doi:10.1007/s00104-023-01830-z · Cited by 3
Pharmacologic management for polycystic ovary syndrome: Weight loss
Nadeem, S., & Merchant, A. A. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87932-3.00025-6 · Cited by 1
Obesity and Diabetes: Clinical Aspects
Wharton, S., Christensen, R. A. G., Costanian, C., Gershon, T., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_41 · Cited by 1
How to apply the Canadian Obesity Clinical Practice Guidelines to people with type 2 diabetes
Pedersen, S. D. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.115 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Type 2 Diabetes and Pre-Diabetes in Pediatric Obesity
Bensignor, M. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_9 · Cited by 1
Carbone, E. A., Caroleo, M., Rania, M., de Filippis, R., Condoleo, F., Catalano, F., Aloi, M., Fazio, P. D., Arturi, F., Hribal, M. L., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12020451 · Cited by 3
Guidelines for obesity clinic consultations in primary healthcare clinics
Kang, J., & Kim, K. K. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.4.240 · Cited by 3
Diabetes and Weight Management
Brown, C. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580406482.ch14 · Cited by 1
Beran, M., Ekstrom, H. L., Crain, A. L., Hooker, S. A., Chumba, L. N., Appana, D., Kromrey, K., Kunisetty, G., McKinney, Z. J., Pronk, N. P., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107830 · Cited by 1
Medical Approaches to Weight-Centric Management of Obese Patients with Type 2 Diabetes
Ryan, D. H. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3220-7_4 · Cited by 1
Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options.
Plodkowski, R. A., McGarvey, M. E., Reisinger‐Kindle, K., Kramer, B., Nelson, E. B., Lee, J., & Nguyen, Q. T. (2016) · Europe PMC (PubMed Central) · Cited by 1
Self-citationDay, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00026-9 · Cited by 2
Vijay., J., Natarajan., P., Gokul., V., Janani., A. M., & Mumthaj., P. (2021) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2021.v68i01.011 · Cited by 3
Medications Indicated for Chronic Weight Management
Ryan, D. H., & Yockey, S. R. (2019) · Endocrinology · doi:10.1007/978-3-319-46933-1_31 · Cited by 1
Garelli, S., Salituro, N., Pontesilli, G. M., Ricciardiello, L., Vicennati, V., & Pagotto, U. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65344-8 · Cited by 2
Rubio-Almanza, M. (2019) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14103.2019.664939 · Cited by 2
Adjunctive Therapy, Including Pharmacotherapy
Al-Bazz, D. Y., & Wilding, J. P. H. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch21 · Cited by 1
Aslan, A., Mert, T., Uçaner, B., Hançerlioğulları, O., Karaman, Ç., Çiftçi, M. S., Acar, S., Göktaş, S. S., Anadolulu, Z., Özkara, M., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2641 · Cited by 1
Central Nervous System Stimulants and Drugs That Suppress Appetite
Zahner, M. R., & Bello, N. T. (2016) · Side effects of drugs annual · doi:10.1016/bs.seda.2016.07.007
Naltrexone/bupropion prolonged release
Llano, A. (2015) · Practical Diabetes · doi:10.1002/pdi.1938
Il trattamento antidepressivo: effetti sul peso corporeo
Marsano, A., Porcelli, S., Serretti, A., & Scudellari, P. (2015) · L Endocrinologo · doi:10.1007/s40619-015-0100-y
“Il bupropione potrebbe essere considerato l’antidepressivo di prima scelta in pazienti obesi e la terapia combinata con bupropione e naltrexone a rilascio prolungato in pazienti obesi affetti da diabete di tipo 2 si è rivelata in grado di indurre una riduzione del peso corporeo, associata a un miglioramento del contro…”
BackgroundBuehler (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s77881
Pharmacological management of obesity in patients with type 2 diabetes
Black, R. L., Higbea, A. M., Duval, C., & Chastain, L. M. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1220300 · Cited by 1
“Of note, this study excluded patients older than 70 years of age, which limits the applicability of these results to this population [33].”
BackgroundANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA
Tamargo, J. L. (2016)
Naltrexone/Bupropion ER for the treatment of obesity
Elisaf, M., Pappa, E. T., & Filippatos, T. D. (2017) · doi:10.23803/hja.v7i4.97.g60
Medications Indicated for Chronic Weight Management
Ryan, D. H., & Yockey, S. R. (2017) · Endocrinology · doi:10.1007/978-3-319-47685-8_31-1 · Cited by 1
Central Nervous System Stimulants and Drugs That Suppress Appetite
Bello, N. T., & Zahner, M. R. (2017) · Side effects of drugs annual · doi:10.1016/bs.seda.2017.07.007
Chapman, L. E., Alexander, R., Keyserling, T. C., & Ammerman, A. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-71812-5_6
Evaluation and Treatment of Insulin Resistance and Hyperglycemic States
Hurley, D. L., & Zangeneh, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-95655-8_13
Saunders, K. H. (2018) · Springer eBooks · doi:10.1007/978-3-030-01039-3_13
Wharton, S., Costanian, C., Gershon, T., & Christensen, R. A. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_39 · Cited by 2
Anti-Obesity Medications: An Update for Canadian Physicians
Modi, R., Kabani, R., Dang, J. T., Chapelsky, S., & Sharma, A. M. (2020) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v15i4.394 · Cited by 1
Influencia de la cirugía bariátrica sobre antropometría, metabolismo y calidad de vida
Calvo, S. G. (2021) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/46437 · Cited by 2
Olszanecka‐Glinianowicz, M., Dudek, D., Filipiak, K. J., Krzystanek, M., Markuszewski, L., Ruchała, M. A., & Tomiak, E. (2020) · Nutrition Obesity & Metabolic Surgery · doi:10.5114/noms.2020.97921 · Cited by 3
“Efficacy: a total of 12,868 patients participated in the clinical trials of bupropion and naltrexone combination COR III phase and LIGHT IV phase, with a weight loss of at least 5% at baseline in 53-80% (depending on the study) for 56 weeks, and 10% in 26-55% [31-35].”
BackgroundPharmacologie de l'obésité : vers de nouvelles options
Clément, K., & Ziegler, O. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-76753-1.00116-8 · Cited by 1
Typ-2-Diabetes: Gewichtsreduktion per stufenweiser Eskalation
Blüher, M. (2021) · Deutsches Ärzteblatt · doi:10.3238/persdia.2021.11.05.07
Treatment of Obesity in the Patient with Type 2 Diabetes
Mundi, M. S., & Collazo–Clavell, M. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_43
Zhao, N., Gu, Z., Li, L., Jiang, M., Chen, W., Liu, B., Zhu, J., Guo, Y., He, X., Zhang, C., et al. (2020) · doi:10.21203/rs.3.rs-109514/v1
Oroko, M., Llano, A., & Fisher, M. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch13
Novel drugs in pharmacotherapy of obesity
Hartinger, J. M. (2021) · Praktické lékárenství · doi:10.36290/lek.2021.015
“Bylo zjištěno, že účinnost léku je nižší (i když statisticky stále významně lepší oproti placebu) u pacientů s DM (studie NB-304) (22) a analýza podskupin ukazuje, že nižší efektivita léčby se projevuje již u pacientů s vyšší glykémií nalačno (tedy ve fázi prediabetu) (19).”
Clinical Evaluation, Lifestyle, and Pharmacological Management of Obesity
Kolli, S., Tchang, B. G., Redmond, I. P., Barenbaum, S. R., & Saunders, K. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94953-2_14
Kapfhammer, H. (2022) · Springer eBooks · doi:10.1007/978-3-662-65873-4_4
Nutritional Principles in the Treatment of Diabetes
Middelbeek, R. J. W., Hafida, S., & Groysman, A. Y. (2023) · Nutrition and health · doi:10.1007/978-3-031-24663-0_5
Treatment: Lifestyle and Medication
Khan, A. A., & Hamdy, O. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_29
El-Naas, R., Barenbaum, S. R., Shukla, A. P., & Aronne, L. J. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-39721-9_10
Finer, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch18
Abdel-Malek, M., Thayabaran, D., & Miras, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00010-3
COŞKUN, O. (2024) · doi:10.5152/8516
Bariyatrik Cerrahi Sonrası Sarkopeni: Tanı, Yönetim ve Önleme Stratejileri
Gönenli, M. G. (2024) · doi:10.5152/8522
Adolesanlarda Bariyatrik Cerrahi
Aslan, A., Ebiloğlu, M. F., & Aygen, E. (2024) · doi:10.5152/8509
Polat, S. H. B., & Yumuk, V. (2024) · doi:10.5152/8510
Bariatrik ve Metabolik Cerrahi Genel Prensipler ve Yenilikler II
Taşkın, M., Taşkın, H. E., Zengin, S. Ü., Bedirli, A., Aslan, A., Çalışır, A., Süsleyici, B., Kayaalp, C., Bilgiç, Ç., Büyükkasap, Ç., et al. (2024) · doi:10.5152/8500
Bariatrik ve Metabolik Cerrahi Yapılacak Merkezin Özellikleri ve Gereksinimleri
Bostancı, E. B., & Çolakoğlu, M. K. (2024) · doi:10.5152/8504
Revizyon Cerrahisinde Teknikler ve Adım Adım Revizyon
Omarov, T. I. (2024) · doi:10.5152/8501
Gastrik Bypass Cerrahisi Sonrası Kaçakların Cerrahi Tedavi Seçenekleri
Sobutay, E., BILGI, Ç., & Yavuz, Y. (2024) · doi:10.5152/8521
Obezite Önleyici İlaçların Farmakogenomiği
Duman, B. S. (2024) · doi:10.5152/8520
Süper Obez ve Uzun Dönem Kronik Hastalığı Olan Hastalarda Yönetim
YILMAZ, H., & Çalışır, A. (2024) · doi:10.5152/8512
Obezite ve Metabolik Cerrahide Yeni Teknolojiler
Pehlivan, M., & ÇETIN, M. F. (2024) · doi:10.5152/8518
Bariatrik ve Metabolik Cerrahide Robotun Yeri
Kaplan, K., & Çetinkünar, S. (2024) · doi:10.5152/8502
Polat, S. H. B., & Yumuk, V. (2024) · doi:10.5152/8523
Kritik Durumdaki Bariyatrik Metabolik Cerrahi Hastasının Yoğun Bakım Takibi
Köksal, G. M. (2024) · doi:10.5152/8514
Sleeve Gastrektomi Kaçakları Sonrası Cerrahi Tedavi
Bılecık, T. (2024) · doi:10.5152/8505
Kompleks Revizyonlarda Robotik Revizyonel Bariatrik Cerrahi
Bedirli, A., Büyükkasap, Ç., & KARABACAK, H. (2024) · doi:10.5152/8517
Yaşlılarda Bariatrik ve Metabolik Cerrahi
Acar, F. (2024) · doi:10.5152/8511
NALTREKSONO-BUPROPIONO VARTOJIMO SU KITAIS PSICHOTROPINIAIS VAISTAIS SAUGUMAS
Butnoriūtė, E., & Musneckis, A. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.215
Current Approach of Diabetes Mellitus in Obese Patients
Karaburgu, S. (2023) · doi:10.69860/nobel.9786053359111.8
Medically Supervised Weight Loss and Effects of Anti-Obesity Medications
Sheer, A. J., Donahoo, W. T., & Johnson-Mann, C. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_14
Lyu, Y. S., Ahn, H. Y., Hong, S., & Park, C. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s512114
Şimşek, C., & Thompson, C. C. (2024) · Springer eBooks · doi:10.1007/978-3-031-70004-0_3
Introduction to Obesity and Anti-obesity Medications
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_1
Fixed Combination Anti-obesity Medications
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_3
Writing Task Force iCARDIO-Alliance (2025) · Global Cardiology · doi:10.4081/cardio.2025.71 · Cited by 1
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Varra, F., Varras, M. N., Varra, V., & Theodosis‐Nobelos, P. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328392698250818071803 · Cited by 3
Lifestyle Management of Hypertension and Type 2 Diabetes
Kim, J. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.3.120
Medications for the Management of Obesity
Giruzzi, N. R. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch29
Schmiedel, O., Ivey, M. K., Karunasinghe, N., & Murphy, R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100240
“The safety profile, including the rate of withdrawal and treatment-related adverse events, was like that of the COR studies, where gastrointestinal and neurological side effects were the most frequently reported adverse events [36 – 38].”
InfluentialA consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Anti-obesity Pharmacotherapy for Transplant Recipients
Haugen, C. E., & Orandi, B. J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01388-1 · Cited by 1
“Orlistat can also with improvements in blood glucose and dyslipidemia but not blood pressure [71–74 ].”
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., Schmitz, S. H., & Subramanian, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00020-3
Treatment of obesity: New drugs
Berti, S., Garelli, S., & Pagotto, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00330-7
Tronieri, J. S., Kushner, R. F., Apovian, C. M., Fitch, A., Still, C. D., & Wadden, T. A. (2026) · Obesity · doi:10.1002/oby.70183 · Cited by 1
General Principles of Psychopharmacology
Giakas, J. A., & Grossberg, G. T. (2026) · Springer eBooks · doi:10.1007/978-3-032-15772-0_2
Moughaizel, M. (2020) · theses.fr (ABES) · doi:10.70675/d21b4f34z8e9az4348za233z7629490bce9e
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Wallentowitz, L., García, M. G., Atorrasagasti, C., Harms, C., Huhn, E. A., Roser, P., Verlohren, S., Giesen, E. M., & Blois, S. M. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10053-6 · Cited by 4
Adipositas und Diabetes mellitus Typ 2 (Update 2026)
Brix, J. M., Clodi, M., Harreiter, J., Hoppichler, F., Fw, K., Itariu, B.-K., Parzer, V., Resl, M., Schindler, K., Toplak, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02706-y
“Beide Präpara-te zeigten auch in Studien bei Menschen mit Typ-2-Diabetes einen moderaten Gewichtsverlust sowie eine HbA 1c -Verbesserung [59, 60].”
Regulators of appetite in mammals—old and new players
Fernandes, J. H., Silva, J. D., Costa, M. D., & Maciel, P. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag020 · Cited by 1
Long-term effects of weight-reducing drugs in people with hypertension
Spary-Kainz, U., Posch, N. A. S., Radl-Karimi, C., Jeitler, K., Krenn, C., Siebenhofer, A., Berghold, A., Horvath, K., Winterholer, S., & Semlitsch, T. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub6 · Cited by 1
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
“The efficacy of N/B combination on BW loss, glycemic, and CV parameters has been evaluated in a 56-week RCT with 505 overweight/obese patients with T2DM, with or without background of oral antidiabetic drugs (OADs) use [37].”
Varra, F., Theodosis‐Nobelos, P., Varra, V., & Varras, M. N. (2026) · Medicina · doi:10.3390/medicina62081445
Kushner, R. F., Iceta, S., Tronieri, J. S., Still, C. D., Fitch, A., & Apovian, C. M. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.08.001
Mackey, S., Egan, C., & Elkind-Hirsch, K. E. (2026) · Therapeutic Advances in Reproductive Health · doi:10.1177/26334941261481473
Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ahmad, I., Azmi, S., Albabtain, M. A., Mustafa, M., Kunnathodi, F., Riyasdeen, A., AlWhaiby, B. R., Alharbi, E. M., Arafat, A. A., & Alotaibi, H. F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101281
“The COR-I, COR-II, COR-BMOD, and COR-Diabetes trials demonstrated weight reductions of 6.1–11.5% with NB versus 1.2–5.1% with placebo [65–67 , 96 ].”
InfluentialBurguera, B. G., Griebeler, M. L., & Al-Husni, D. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.09.003
Metadata
- Authors
- Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group
- Affiliations
- Baylor University Medical Center (US)
- Pennington Biomedical Research Center (US)
- Scripps Clinic (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Orexigen Therapeutics (United States) (US)
- Corresponding author
- Hollander, Priscilla
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-11-13
- Volume
- 36
- Issue
- 12
- Pages
- 4022-4029
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3836105
- OpenAlex
- W2020982355
- Cited by
- 501
- References
- 39
- Citations by year
- 2026: 29 · 2025: 50 · 2024: 56 · 2023: 51 · 2022: 35 · 2021: 47 · 2020: 34 · 2019: 27 · 2018: 34 · 2017: 40 · 2016: 42 · 2015: 43 · 2014: 12 · 2013: 1
- FWCI
- 23.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-02-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- naltrexone/bupropion, combination therapy, type 2 diabetes, obesity, overweight, weight loss, glycemic control, HbA1c, triglycerides, HDL cholesterol, nausea, constipation, vomiting, antidepressant side effects, cardiovascular risk factors, lifestyle intervention, drug safety, drug efficacy, suicidal ideation, hypoglycemia
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Obesity, Retrospective Studies, Risk Factors, Weight Loss, Bupropion, Treatment Outcome, Antidepressive Agents, Second-Generation, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.